UPDATED May 01, 2024
All the companies in the healthcare sector, including healthcare provider and equipment, healthcare tech, pharmaceuticals, biotech and life sciences.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
LLY | US$755.91 | 4.3% | 76.4% | US$699.4b | US$848.35 | PE110.9x | E27.0% | 0.7% | Pharmaceuticals & Biotech | ||
UNH | US$492.97 | -0.2% | 1.2% | US$445.4b | US$567.36 | PE29.5x | E19.5% | 1.5% | Healthcare | ||
JNJ | US$149.92 | 2.1% | -7.5% | US$363.8b | US$173.26 | PE18.8x | E5.1% | 3.3% | Pharmaceuticals & Biotech | ||
MRK | US$128.26 | -1.9% | 9.3% | US$326.3b | US$141.64 | PE140.9x | E24.9% | 2.4% | Pharmaceuticals & Biotech | ||
ABBV | US$160.81 | -3.9% | 9.1% | US$286.3b | US$182.31 | PE47.9x | E23.3% | 3.9% | Pharmaceuticals & Biotech | ||
AZN | UK£121.70 | 1.2% | 2.7% | UK£188.7b | UK£131.45 | PE37.3x | E16.5% | 2.0% | Pharmaceuticals & Biotech | ||
TMO | US$571.25 | -0.08% | 4.7% | US$219.5b | US$625.47 | PE36.1x | E10.6% | 0.3% | Pharmaceuticals & Biotech | ||
ABT | US$105.92 | -0.9% | -4.5% | US$184.4b | US$126.09 | PE32.8x | E11.3% | 2.1% | Healthcare | ||
DHR | US$246.84 | 0.4% | 1.9% | US$182.9b | US$272.68 | PE44.9x | E13.5% | 0.4% | Pharmaceuticals & Biotech | ||
PFE | US$27.70 | 9.7% | -27.5% | US$153.9b | US$31.89 | PE73.5x | E22.0% | 6.1% | Pharmaceuticals & Biotech | ||
AMGN | US$278.39 | 3.3% | 20.1% | US$148.8b | US$302.90 | PE22.2x | E9.1% | 3.2% | Pharmaceuticals & Biotech | ||
ISRG | US$377.65 | 1.2% | 24.6% | US$131.8b | US$420.38 | PE67.4x | E11.6% | n/a | Healthcare | ||
SYK | US$326.63 | -3.1% | 14.8% | US$124.8b | US$372.35 | PE37x | E10.5% | 1.0% | Healthcare | ||
ELV | US$525.61 | -2.6% | 15.1% | US$122.0b | US$603.15 | PE19.6x | E12.4% | 1.2% | Healthcare | ||
MDT | US$80.92 | 2.1% | -9.4% | US$107.4b | US$94.77 | PE25.6x | E9.7% | 3.4% | Healthcare | ||
BSX | US$72.03 | -1.7% | 38.7% | US$106.2b | US$81.00 | PE60x | E18.1% | n/a | Healthcare | ||
VRTX | US$400.16 | 0.6% | 15.5% | US$103.9b | US$460.23 | PE28.6x | E11.4% | n/a | Pharmaceuticals & Biotech | ||
CI | US$344.50 | -2.8% | 41.4% | US$101.3b | US$386.41 | PE18.9x | E10.0% | 1.6% | Healthcare | ||
REGN | US$937.61 | 5.3% | 24.4% | US$97.5b | US$1,037.45 | PE25.6x | E11.4% | n/a | Pharmaceuticals & Biotech | ||
BMY | US$43.70 | -2.2% | -34.6% | US$89.6b | US$53.32 | PS1.9x | E43.1% | 5.5% | Pharmaceuticals & Biotech | ||
GSK | UK£17.05 | 3.9% | 16.3% | UK£69.5b | UK£20.20 | PE15.5x | E11.3% | 3.4% | Pharmaceuticals & Biotech | ||
CSL | AU$275.39 | -1.1% | -8.2% | AU$132.6b | AU$306.40 | PE35.2x | E14.7% | 1.3% | Pharmaceuticals & Biotech | ||
HCA | US$308.84 | -1.7% | 11.2% | US$81.8b | US$344.35 | PE14.9x | E6.1% | 0.9% | Healthcare | ||
GILD | US$65.33 | 0.09% | -16.8% | US$81.7b | US$83.46 | PE168x | E36.7% | 4.7% | Pharmaceuticals & Biotech |